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Abstract Complete portacaval shunt was used to treat 10 patients with glycogen 
storage disease. A favourable effect was noted on body growth and a number of 
metabolic abnormalities. More recently. continuous night feedings with an 
intermittently placed gastric tube or through a gastrostomy has been shown to 
be helpful either before or after portacaval shunts. Such alimentation techniques 
may eliminate the need for shunts in some patients and be of adjuvant benefit in 
others. 
Portacaval shunt was also used for three children who had homozygous Type II 
hyperiipidaemia. Substantial reductions in serum cholesterol concentration were 
observed. as well as resorption of xanthomas. Reversal of some cardiovascular 
lesions has been documented. 
The benefits of portacaval shunt in these disorders is probably due to the change 
in the hormone climate of the liver and the whole organism brought about by 
diversion of the hormone-rich splanchnic venous blood around the liver. 
Earlier during this symposium we described how diversion of hepatotrophic 
substances around the liver with portacaval shunt influenced liver structure and 
function in many species, including man, and we discussed the possible mech-
anisms of these changes in the general context of alterations of the hepatic hor-
monal milieu (Starzl et al., pp. 111-129). There are many clinical implications 
of this hepatotrophic concept, as other contributors will enumerate. Here, we 
shall confine our remarks to portacaval shunt for glycogen storage disease and 
for Type II byperlipidaemia. Our present understanding is that the metabolic 
gains thereby obtained in these diseases are paid for by placing the liver at a 
specific physiological disadvantage. 
GLYCOGEN STORAGE DISEASE 
When portal diversion was first performed for glycogen storage disease almost 
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If. PORTACAVAL SHUNT THERAPY 313 
14 years ago (Starzl et al. 1965), the rationale for the procedure was different 
from what it is today. Then, it was hoped that by short-circuiting splanchnic 
venous blood around the liver, glucose would be made more readily available 
to peripheral tissues with relief of hypoglycaemia, and that the liver would be 
coincidentally deglycogenated. As the content of this symposium has made 
clear, the consequences of portacaval shunt are far more subtle and wide-
ranging than that simple view suggests. 
That first patient who had Type III glycogen storage disease is still alive 
almost 14 years after portacaval transposition. A patient similarly treated by 
Riddell et al. (1966) also survived chronically. Because our second patient 
died two days after portacaval transposition this procedure was abandoned. 
Simple portacaval shunts were used for all of the eight subsequent patients in 
our series, of whom seven are alive with follow-ups of eight months to more 
than five years (mean 60 months). Sporadic further cases summarized four 
years ago (Starzl et al. 1973a) confirmed the value of portacaval shunt for 
palliation of these children's condition. By this time, Folkman et al. (1972) 
had added an important therapeutic dimension by showing how preoperative 
parenteral hyperalimentation would reduce the operative risk by normalizing 
pre-existing hep'atomegaly, acidosis and other abnormalities, including hyper-
lipidaemia. A final development has been the refinement of overnight feeding 
techniques as an alternative to portacaval shunt or as an adjuvant to the oper-
ation (see later). 
The ages of our 10 patients, types of disease, and symptoms are summarized 
in Table 1. Type I disease (glucose-6-phosphatase deficiency) has been the 
most common indication for treatment, with Type III disease (amylo-l ,6-
glucosidase deficiency) being a distant second. 
Metabolic effects 
After portal diversion, most of the children who had pre-existing hypoglyc-
aemia did not have relief of this problem or the relief was not complete. Thus, 
night" feedings usually had to be continued. Studies of plasma insulin and 
glucagon in several of these patients have revealed the interesting pattern shown 
in Fig. 1. The flat peripheral insulin curves typical of Type I glycogen disease 
(Lockwood et al. 1969) became significantly elevated after portacaval shunt, 
and there were smaller increases in glucagon. The glucose tolerance curves 
were much the same before and after operation. Liver glycogen concentrations 
in all the patients later biopsied were not changed. 
In spite of failure to alter the hepatic glycogen concentration, the liver size 
in several of our patients and those reported by others underwent a very ob-
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FIG. I. Plasma insulin and glucose concentrations before and after portacaval shunt in a child 
(Case 8, Table I) with Type I glycogen storage disease. 
vious reduction as measured with liver scan planimetry. Even if obvious 
shrinkage did not occur, postoperative biopsies always showed a diminution 
in individual hepatocyte size similar to that produced in animals by portacaval 
shunt (Starzl et 01. 19730). 
In contrast to the incomplete relief of hypoglycaemia, all components of 
the hyperlipidaemia which is a characteristic of the Type I disease had profound 
and permanent relief (Fig. 2) as was first observed by Hermann and Mercer 
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FIG. 2. Effect of parenteral hyperalimentation and end-to-side portacaval shunt on the plasma 
lipids of Patient 4 whose diagnosis was Type I glycogen storage disease. Note the rapid and 
relatively complete reversal of all abnormalities. (From Starzl et al. 1973a, by permission of 
Annals of Surgery.) 
TABLE 2 
Growth rate and complications after portal diversion for glycogen storage disease 
Case 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Mea.n: 
Growth rate 
rem/month over 40-120 months) 
0.49 
Operative death 
0.50 
0.28 
0.53 
0.62 
0.50 
0.49 
0.88 
0.54 
Complications 
Macroadeoomatosis 
Died 41 years after shunt. Primary pulmonary 
hypertension, NH3 = 85, macroadenomatosis 
Renal artery stenosis surgically corrected 32 
months after shunt 
Renal stone 2 months after shunt. Mild arterial 
hypertension, macroadenomatosis 
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316 T. E. STARZL et al. 
FIG. 3. The dramatic wrist and hand bone growth and mineralization in Case 3 in the first II! 
postoperative months. The bracket on the left index finger is 5 em. in length. (From Starzl 
el al. 1973a, by permission of Annals of Surgery.) 
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(1969) and confirmed by Folkman et al. (1972) and in our own cases (Starzl 
et al. 1973a). Correction of other metabolic defects was observed including 
abnormal bleeding, uric acid elevations, and abnormal calcium metabolism 
(Starzl et al. 1973a). 
Growth 
All 10 of our patients had growth retardation before portacaval shunt. 
Afterwards, height increases, which in most cases had virtually ceased, have 
occurred at the rates listed in Table 2, approximately 0.5 cm per month. 
Quantitative measures of growth were obtained with radiographic techniques 
(Starzl et af. 1973a). An example of the results is shown in Fig. 3. Comparison 
of the wrist and hands in this seven-year-old stunted child before and 11 t months 
after operation showed the phenomenal effects of bone age doubling. In addi-
tion to the size change, mineralization occurred and the appearance of new wrist 
bones. Circulating somatotropin in these patients was normal. The growth 
spurts may have been at least partially attributable to the increased insulin 
distribution to the periphery mentioned earlier (see Fig. 1) since, in recent years, 
insulin has been recognized to be a major growth hormone, comparable in 
potency to somatotropin. 
Encephalopathy and other risks 
None of our patients has developed hepatic encephalopathy. The highest 
blood ammonia concentration recorded was 84 pg % in a child who died al-
most five years after portacaval shunt during an attempt at transcaval radio-
graphic visualization of the portacaval anastomosis. This patient (no. 4) had 
not achieved the full expected growth after operation (Table 2), had mild 
systemic hypertension, and had unexplained transient bouts of cyanosis, hyper-
ventilation, and unconsciousness. Except for the slightly elevated blood am-
monia concentration, liver function was normal. 
At autopsy, the liver had macroadenomatosis. Very minor protoplasmic 
astrocytosis was in the brain. A finding that had not been $uspected during 
life was advanced right ventricular hypertrophy and dilatation. The smaller 
pulmonary arteries and arterioles had medial muscle hypertrophy, medial and 
intimal fibrosis, scattered fibrinoid necrosis, and numerous plexiform lesions. 
In retrospect, the patient died from a cardiopulmonary complication of the 
kind that has been documented in patients with Type I glycogen storage disease 
or other liver disease (Levine et al. 1973). 
The complication has been termed yasocoustrictive pulmonary hypertension. 
'f I 
:' . 
: I 
; I 
: , 
, , 
· , 
· I 
• I 
, I 
· . 
· I 
· , 
: I 
, , 
· I 
( . 
: . 
I· 
• 
I. 
318 T. E. STARZL et al. 
It has been speculated that a humoral vasoconstrictive agent, which normally 
is completely detoxified by the liver, is responsible for the hypertrophic lesions 
in the pulmonary vasculature. It is conceivable although unlikely that the 
development of a renal art~ry stenosis in patient No.5 could have been by the 
same mechanism. 
Three of our 10 patients developed the hepatic lesions which have been 
termed both macroadenomatosis and nodular hyperplasia. Filling defects were 
noted by liver scan with some waxing and waning of size. This complication 
is common in patients with Type I glycogen storage disease particularly with 
advancing age and was recently reported in seven of eight patients who were 
three to 28 years old (Howell et al. 1976). 
The value of night feedings 
The failure of overnight hypoglycaemia to be relieved after portal diversion 
has already been mentioned. Partly for this reason, the continuous night feed-
ing through a gastrostomy or gastric tube recently advocated by Burr et aJ. 
(1974) and Greene et al. (J976) has been a useful if not mandatory adjuvant 
in some of our cases. Glucose or amino acid mixtures have both been effective. 
The night feedings have contributed to or been primarily responsible for the 
same kinds of growth spurts and relief of metabolic abnormalities (including 
hyperIipidaemia) as are ameliorated by portacaval shunt. Greene et al. (1976) 
have shown that systemic plasma insulin levels are more than doubled by such 
treatment and that glucagon is decreased, leading them to speculate that the 
hormone changes were responsible for the benefits. Whatever the explanation, 
this kind of treatment is an alternative to portal diversion as the primary treat-
ment of children with glycogen storage disease, and even after portacaval shunt 
it has an additional value. 
HYPERUPIDAEMIA 
In the glycogen storage diseases we have been discussing, the livers are al-
ways patently abnormal because of the accumulation of glycogen, and often 
because of fibrosis. By contrast, the liver in homozygous Type II hyperlipo-
proteinaemia is morphologically normal. The reasons for the elevated serum 
cholesterol and the low density lipoproteins in this autosomal dominant in-
herited disorder are by no means understood. 
Whatever its cause, the homozygous form of Type II hyperlipoproteinaemia 
has a shockingly poor prognosis even with attemps at rigid medical therapy. 
Lipid-rich deposits are laid down in widely separated ~upaficial and deep parts 
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FIG. 4. The hands of Patient 1 of the hyper1ipidaemia series two weeks before (left) and 16 
months after (right) portacaval shunt. 
of the body (Fig. 4). and the same accumulations cause advanced aortic stenosis 
and coronary artery disease which are responsible for death before the age of20 
years in the usual case. 
In an effort to reduce the serum cholesterol and lipoprotein levels, we per-
formed an end-to-side portacaval shunt on March I, 1973, in an II-year-old 
girl with homozygous Type II hyperlipoproteinaemia that was refractory to 
medical treatment (Starzl et al. 1973b). The patient had suffered a myocardial 
infarction about two months previously. After surgery, the serum cholesterol 
values fell from about 800 mg/IOO ml to levels that were consistently below 400 
rog/IOO rol (Fig. 5). Unsightly xanthomas began to resOib from visible sub-
cutaneous and tendinous locations. At the same time, attacks of the pre-existing 
angina pectoris became less frequent and finally stopped. From cardiac cathet-
erization 16 months after the end-to-side portacaval shunt was performed, there 
was good evidence that aortic stenosis had been reversed with a diminution of 
the aortic valve gradient from 56 to 10 mmHg (Starzl et al. 1974a). The coron-
ary arteries were also thought to be less diseased than before, although three 
stenoses were still present. More than It years later, the girl died suddenly while 
coming home from school. The autopsy findings led to the conclusion that 
death was caused by an acute cardiac arrhythmia related to the residual coronary 
artery disease or to the earlier myocardial infarction (Starzl et al. 1974b). 
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FIG. 5. Serum cholesterol concentrations after portacaval shunt in Patient I, Table 3. 
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The portacaval shunt was widely patent. The liver, which weighed 618 g, 
was grossly normal, and microscopically it was unchanged from the biopsy spec-
imen that was obtained six months postoperatively. On light and electron mi-
croscopy, the most prominent findings were shrinkage of the hepatocyte size, 
depletion of rough endoplasmic reticulum, and the accumulation of intracyto-
plasmic lipid deposits. These changes are typical of the portaprival condition 
in all species, as we mentioned earlier (Starzl et 01., this volume, pp. /11-129). 
Hepatic function had not been changed by portacaval shunt as judged by stan-
dard liver function tests. 
We have performed a portacaval shunt on two more patients with the same 
diagnosis (Cases 2 and 3, Table 3). Patient 2 is a seven-year-old girl who had 
preoperative serum cholesterol values that averaged 997 ±47 (S.D.) mg/IOO ml 
while she was on a very low cholesterol diet. Six months after the shunt, the 
cholesterol level measured in the same laboratory was 600 mg/lOO ml (a 40 % 
reduction), despite a relaxation of the diet, and now the cholesterol concentra-
tions are about 450-500 mg/lOO ml (Table 3). This child also had aortic 
stenosis and angina pectoris. Because of persistence of her cardiac disease, she 
was treated with aortic and mitral valve replacement plus double coronary 
artery by-pass two years after portacaval shunt. She is well. 
Our third patient has had a reduction in serum cholesterol from 1000 mg/IOO ml 
to 600-650 mg! 100 ml in the 21 months since the operation (Table 3). Although 
the cholesterol falls were less striking than in our first two patients, visible 
xanthomas are slowly resorbing and the patient is asymptomatic. 
The changes in peripheral insulin content in these patients have been analo-
gous to those in patients treated for glycogen storage disease, but starting with 
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FIG. 6. Systemic venous plasma glucose, insulin and glucagon concentrations in Patient 2 with 
hyperlipidaemia before and after portacaval shunt. Stimulus was glucose meal. 
preoperatively normal values. Postoperatively, systemic venous insulin and 
glucagon values were both increased, especially the former (Fig. 6). 
None of our three patients with hyperlipidaemia has had any signs of hepatic 
encephalopathy. Nevertheless, this clinical application for hyperlipidaemia, 
as in the patients with glycogen storage disease, accepts a 'trade-off' of distinctly 
suboptimal conditions of liver perfusion in return for metabolic improvements 
that are derived from these suboptimal conditions. Realization of this fact 
has encouraged us to maintain a conservative and discriminating attitude 
about the recommendation of portacaval shunt for either kind of inborn error. 
The freedom from encephalopathy in our cases may be partly due to the fact 
that we have treated children only. 
Other reports 
Shortly after portacaval shunt was first proposed for the treatment of hyper-
lipidaemia, a plea was made by Ahrens (1974) that all such patients be care-
fully studied and faithfully reported to a central registry. Knowledge has been 
acquired in this way about more than 30 patients. More importantly, formal 
reports have appeared in the literature on nine of these cases in addition to 
our own three (Krogh & Wickens 1974; Stein et al. 1975; Russell et al. 1976; 
Cywes et al. 1976; Farriaux et al. 1976; Weglicki et al. 1977). The degree of 
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serum cholesterol lowering has been variable from patient to patient, as in 
our three cases, but it seems established beyond doubt that a significant fall 
can be expected if the shunt is patent. Resorption of the xanthomas and relief 
of angina have also been common. Failure to observe an antilipidaemic effect 
has been associated with thrombosis of the shunt (Cywes et al. 1976; Farriaux 
et al. 1976). 
Mechanism of effect 
Our studies in the dog (Starzl et al. 1975) and investigations in the rat 
(Magide et al. 1976), pig (Carew et af. 1976; Chase & Morris 1976), and human 
(Bilheimer et al. 1975) have shown or suggested that a reduction in hepatic 
cholesterol synthesis is responsible. Only the report of Coyle et af. (1976) in 
dogs has denied this. Other factors may contribute to the antilipidaemic effect, 
as Ahrens (1974) has speculated. 
Our experiments have suggested that the main reason for decreased hepatic 
cholesterol synthesis is deprivation of the liver of insulin (Starzl et al. 1975). 
Eaton (1976) has recently proposed that the changes in glucagon metabolism 
may be important. 
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Discussion 
Smith-Laing: 00 you attribute the fall in lipids in the hyperlipidaemic pa-
tients to a general decrease in metabolic processes in the liver? Have you 
looked at any other synthetic process, such as the rate of synthesis of albumin, 
to see if it is correlated with the fall in lipids? 
Starzl: The answer to your first question is yes. The answer to the second 
question is no,' we haven't. I think the fall in cholesterol concentration is 
mainly due to a decrease in hepatic cholesterol synthesis, which in dogs falls 
to about one-seventh after a shunt (Starzl et 01. 1975). Ahrens (1974) has a 
contributory (not alternative) explanation: he suggests that the loss of bile 
acids (by removal of the portal enterohepatic circulation) creates an obligatory 
drain of the cholesterol pool. 
Smith-Laing: Beckelbaum and his colleagues tried complete biliary diversion 
without a shunt in three patients with homozygous hypercholesterolaemia and 
the synthesis of cholesterol kept up with any amount of bile acids that could 
be drained (Beckelbaum et 01. 1977), so presumably it is a combination of 
causes. 
Starzl: Yes. Buchwald et al. (1974) also showed, using an ileal by-pass in 
which the loss of bile acids increased by several-fold, that the rate of cholesterol 
synthesis increased to match the loss. So the chief mechanism seems to be the 
loss of cholesterol synthesis . 
McIntyre: I don't believe that. There is no convincing evidence that it is 
high cholesterol synthesis in the liver which increases serum cholesterol in 
these patients. They have increased amounts of low density lipoproteins 
(LOL). These are not normally produced in the liver; they result from catab-
olism of plasma very low density lipoprotein (VLOL) (Sigurdsson et 01.1975). 
It seems unnecessary to invoke changes 'in hepatic cholesterol synthesis as an 
explanation. Reduced cholesterol synthesis in the liver after a shunt could be a 
consequence of the fall in plasma LOL, because the cholesterol in LDL must 
presumably be cleared via the liver, and excreted in bile either as cholesterol 
or as bile acids. It seems likely that the transfer of LO L cholesterol to the liver 
and its accumulation there might inhibit further synthesis. 
Bloom: What happens to the high density lipoprotein (HOL) level? 
Storz!: Portal diversion has a general antilipidaemic effect in man (affecting 
all the lipid moieties). In animals we found that only cholesterol falls after shunt. 
Leffert: What is the evidence that the liver doesn't produce LDL directly? 
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McIntyre: The studies by the Bethesda group (Eisenberg et al. 1973) suggest 
that the turnover of the p-apoprotein of VLOL accounts for all the turnover 
of LOL apoprotein. Furthermore, if you look for lipoprotein particles in liver 
by electron microscopy you see VLOL but not LOL particles (Marsh 1971). 
Some people think that some LOL is produced in the liver, without good 
evidence. 
Starzl: Hepatic cholesterol or LOL synthesis (or both) have been studied 
in dogs (Starzl et al. 1975), in rats (Edwards et al. 1976; James et al. 1977), in 
pigs (Chase & Morris 1976; Carew et al. 1976) and in a human with Type 11 
hyperlipidaemia (Bilheimer et al. 1975). The cholesterol or LOL synthesis was 
reduced in all these investigations. When both cholesterol and LOL synthesis 
were measured, as was done for example in Bilheimer's patient, they fell 
together. 
McIntyre: It has been claimed that LDL is secreted directly from the liver 
in patients homozygous for Type II hypercholesterolaemia (Soutar et al. 1977). 
The evidence is indirect. If the suggestion is correct we must invoke a special 
mechanism for LDL production in these patients. 
Starzl: You may be correct about a special mechanism, but several of the 
reports J cited did not question the role of the liver in LOL synthesis. I was not 
aware that the connection between cholesterol and LOL metabolism was in 
question in experimental animals or humans. 
McIntyre: The work by Goldstein & Brown (1975) suggests that LOL is 
removed from plasma by various cells, including fibroblasts, which have specific 
LOL receptors. If, as in homozygous Type II hypercholesterolaemia, there are 
no receptors for LOL on the cells, one would expect high cholesterol levels in 
plasma. This is an excellent explanation for the hypercholesterolaemia and 
extremely good evidence must be produced in support of another mechanism 
involving abnormalities of LOL secretion in these patients. 
Leffert: Of the hormones we have been talking about, the group in J. W. 
Porter's laboratory (Ness et al. 1973; Nepokroeff et al. 1974) showed that 
insulin, glucagon, L-triiodothyronine and hydrocortisone regulate HMG-coA 
(P-hydroxy-p-methylglutaryl coenzyme A) reductase. 
O. B. Weinstein and his co]]eagues (personal communication) have shown 
that non-growing adult hepatocytes in culture produce VLOL directly where it 
is secreted into the medium (unpublished studies). If the liver ;s producing 
cholesterol via HMG-coA reductase, what is it doing there? VLOL particles 
contain predominantly triglyceride, not cholesterol. How do you explain the 
cholesterol composition of extrace]]ular LOL derived from VLOL? 
Mc.Intyre: The VLOL apoprotein becomes the apoprotein of LOL; the 
cholesteryl ester content of LDL could be explained by its transfer, with apo-
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protein /3, from VLDL. But it has been claimed that the fatty acid composition 
of the cholesteryl esters in LDL is different from that found in VLDL 
(Goodman 1965). This could be explained by a transfer of cholesteryl ester 
to L 0 L from HDL, either directly or indirectly via VL DL, during the turnover 
process. Lecithin cholesterol acyl transferase (LeAT) certainly appears to be 
responsible for the synthesis of plasma cholesteryl esters. Th 1t enzyme uses 
unsaturated fatty acids rather than saturated fatty acids. 
Why is cholesterol synthesized in the liver? It has always been assumed that 
the liver makes cholesterol to secrete into plasma; but this doesn't make sense, 
because almost all tissues are capable of synthesizing cholesterol. It can't be 
excreted other than by the liver, so the main flow of cholesterol has to be cen-
tripetal for the purposes of excretion. I think we must assume that the liver 
makes cholesterol for bile acid production, and that synthesis is controlled 
and regulated by the input of cholesterol from other tissues via the blood . 
Star=l: What is the reason for the fall in cholesterol LDL and VLDL in 
these patients? 
AI cIntyre: I don't know. It is an extremely exciting observation but I don't 
think an easy answer comes out of it. 
Starzl: May I go to a different topic? As I described in my paper (p. 323), 
there has been a fall in plasma cholesterol after portacaval shunt in almost 
every patient with hyperlipidaemia (about 30 in all throughout the world) 
except three in whom the shunts clotted and in which the tied-off central portal 
vein was re-vascularized through collaterals. Are there clotting disorders in 
these patients? At least one patient (in Europe) had a stroke, a child, a week 
before a shunt was planned. There has been some suspicion of a hypercoagulable 
state which has contributed to the shunt closure in 10 % of the cases and even 
to the other vascular complications. 
Folkman: I have been intrigued by an apparent difference between the coagu-
lation system in children with Type I glycogen storage disease and children 
with hyperIipidaemia Type II. The glycogen storage disease patients often 
have prolonged bleeding times (up to 30-40 minutes), but their platelet counts 
are normal. They may require hospitalization for prolonged nosebleeds. How-
ever, as their high serum lipid levels are brought down to the normal range 
by intravenous glucose or by intragastric feedings of glucose, the bleeding time 
returns to normal (FOlkman et of. 1972). It is thought that the high serum 
lipids in these patients prevent normal platelet agglutination. 
By contrast, children with hyperlipidaemia Type II, who also have high 
lipid levels, have a normal bleeding time, and in some of these children, the 
bleeding time is very short. 
Perhaps this difference contributes to the higher rates of shunt closure in 
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the hyperlipidaemia Type II children who had portacaval shunts than in the 
glycogen storage disease patients who had shunts. 
Weinbren: From a pathological viewpoint, there is a characteristic type of 
atheroma in hyperlipidaemic patients. It is found in the first 4 em of the 
ascending aorta and may involve the coronary ostia. The lesion in the coron-
ary artery in the girl who eventually died was not the usual one. It might 
have been a superimposed thrombus, far down the coronary artery. The others 
seemed to wax and wane with treatment by plasmapheresis. Therefore on the 
angiogram if one finds a lesion along the coronary artery, that may be the one 
to treat with by-pass, but if it is at the ostium, it may recede. 
Starzl: Yes. These lesions in two of our patients were in the ascending 
aorta and in one there was a big atheroma acting almost like a ball valve, and 
presumably compromising the coronary ostia. But in these two patients, in-
cluding one who eventually had a triple coronary artery by-pass, there was 
also peripheral arterial disease. 
In all the early cases of portal diversion for hyperlipidaemia, the patients 
had homozygous disease. There are also heterozygotes but with high levels of 
600-700 mg/100 ml cholesterol. One such patient was recently reported from 
Harvard in which coronary artery by-passes were combined with portacaval 
shunt with good results (Weglicki et al. 1977). Extension from the homozygous 
disease to the heterozygous condition may presage a more frontal assault on 
traditional premature coronary artery disease which involves peripheral vessels . 
Weinbren: We have seen heterozygotes who have lesions in the first part of 
the ascending aorta which may be different from general atheroma in an old 
patient. But full documentation on this point is not yet available. 
Folkman: Why does the glycogen storage disease patient with a very high 
cholesterol level never develop arterial disease? 
M cJntyre: The cholesterol is in different particles; it is presumably not pre-
dominantly in low density lipoproteins, as it is in Type II hypercholesterolaemia, 
but rather in VLDL and chylomicrons. The patients whom Dr Starzl is 
talking about don't have high levels of triglycerides. 
Starzl: The relation of the atherosclerosis in hyperlipidaemia to conventional 
atherosclerotic disease will be interesting to define, particularly if the lesions 
can be reversed. Small & Shipley (1974) looked at the question of the factors 
that would make it possible for atherosclerosis to be cleanly reversed, from a 
physicochemical point of view. The conclusions were somewhat discouraging. 
Although reversal would seem to be possible in terms of lipid removal, a lot of 
residual fibrotic changes cannot be expected to go away. I would therefore 
tend to be much more aggressive than I was with our child who died of coronary 
artery complications. If there was a serious cardiovascular complication, J 
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would combine portal diversion with traditional cardiac surgery approaches. 
McIntyre: If people start to do shunt:> in heterozygote:;, we shall soon know 
all the answers about portal deprivation; they would be excellent people to 
study! 
Star:::l: Yes, and clearly they will respond as well as the homozygotes in 
terms of serum lipid lowering. 
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